Anti-ACE2 IgM Antibody Detection for Severe COVID-19 Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an unmet need for quick diagnosis and detection of markers of severe COVID-19 infection in patients, as existing methods are inadequate in identifying individuals at risk for extended duration of severe symptoms and guiding therapeutic interventions.

Innovation Solution

The method involves detecting the presence of anti-ACE2 IgM antibodies in a biological sample using immunoassays, such as ELISA, to diagnose the probability of severe COVID-19 symptoms and administering appropriate treatments, including immunosuppressing agents or anti-SARS-CoV2 monoclonal antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If existing diagnostic methods are used, then general COVID-19 detection is achieved, but early identification of severe cases and prediction of extended duration symptoms is inadequate

Engineering Contradiction:

Improvedetection accuracy for severe case identificationVSAvoidinformation about disease severity and duration

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent segments the diagnostic approach by detecting specific antibody types (IgM and IgG) against different targets (SARS-CoV-2 spike protein vs. ACE2 receptor). This segmentation allows differentiation between general infection and severe case prediction, where anti-ACE2 IgM antibodies specifically indicate high risk for severe symptoms and extended duration, thereby resolving the contradiction between general detection and precise severity identification

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary diagnostic action by detecting anti-ACE2 IgM antibodies early in the disease course. This preliminary detection of specific biomarkers enables early identification of patients who will develop severe symptoms and extended duration illness, allowing proactive therapeutic intervention before severe manifestations occur, thus improving measurement precision while preventing loss of critical prognostic information

Inventive Principle:

Principle #10Preliminary action

2Loss of time

If early detection of severe cases is implemented, then therapeutic intervention timing is improved, but diagnostic method complexity increases

Engineering Contradiction:

Improvetime to identify severe cases and initiate treatmentVSAvoidcomplexity of immunoassay detection system

Core Design Contradiction:

Loss of timeVSDevice complexity

Solution Approach 1:

The patent employs a multi-functional immunoassay system that can detect multiple antibody types (IgM, IgG) against multiple targets (SARS-CoV-2 spike protein, ACE2 receptor) using a unified platform. This universal approach enables simultaneous assessment of infection status, severity risk, and prognosis within a single diagnostic workflow, reducing time loss while managing complexity through standardized procedures rather than multiple separate tests

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses specific antibodies as intermediary molecules to detect and quantify anti-ACE2 IgM antibodies in patient samples. These intermediary reagents enable the detection system to specifically identify the biomarker associated with severe disease and extended duration, facilitating early case identification through a manageable analytical process that balances sensitivity with operational feasibility

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for early identification of severe COVID-19 symptoms and potential therapeutic interventions, reducing the risk of organ damage and improving patient outcomes by targeting uncontrolled inflammatory mechanisms.

Implementation Method 1

contacting a biological sample from the subject with an antibody that binds to an anti-ACE2 IgM antibody in the biological sample, producing an antibody-anti-ACE2 IgM antibody complex

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

the method comprises an immunoassay to detect the presence of the antibody-anti-ACE2 IgM antibody complex. In some embodiments, the immunoassay is an ELISA assay

Methodology Applied

Scientific EffectELISA detection:

Data Source

PatentUS20240069023A1DETECTION OF ACE2 IgM AUTOANTIBODIES AS MARKERS OF SEVERITY AND MECHANISM IN COVID19 PATIENTS

Publication Date: 2024.02.29 JOHNS HOPKINS UNIVERSITY

AI summary

Provided herein are methods for diagnosing the probability of extended duration of severe COVID19 symptoms in a subject infected with a SARS-CoV2 virus or suspected of being infected with the SARS-CoV2 virus, the method including (a) providing a biological sample from the subject; and (b) detecting the presence of an anti-ACE2 IgM antibody in the biological sample, thereby diagnosing the probability of extended duration of severe COVID19 symptoms in the subject.